Skip to main content

Table 1 The baseline characteristics of patients who visited the emergency department versus those who did not receive care at the emergency department

From: A study of the factors associated with emergency department visits in advanced cancer patients receiving palliative care

Characteristics

No ED visit (N = 134)

ED visit (N = 93)

Demographic data

Age (years), mean (SD)

64.96 (15)

66.28 (14.4)

Gender

 Male, n (%)

59 (44)

56 (60.2)

 Female, n (%)

75 (56)

37 (39.8)

Marital status

 Single, n (%)

22 (16.4)

21 (22.6)

 Married, n (%)

92 (68.7)

58 (62.4)

 Widow, n (%)

13 (9.7)

11 (11.8)

 Divorced, n (%)

7 (5.2)

3 (3.2)

Education

 Uneducated, n (%)

1 (1)

2 (2.7)

 Primary school, n (%)

33 (31.1)

21 (28.4)

 High school, n (%)

39 (36.8)

18 (24.3)

 Bachelor degree or above, n (%)

33 (31.1)

33 (44.6)

Comorbidities

 Hypertension, n (%)

45 (48.4)

26 (19.4)

 Dyslipidemia, n (%)

33 (24.6)

28 (30.1)

 Diabetes mellitus, n (%)

26 (19.4)

25 (26.9)

 Cardiovascular disease, n (%)

7 (5.2)

7 (7.5)

 Cerebrovascular disease, n (%)

7 (5.2)

9 (9.7)

 Cirrhosis, n (%) 

6 (4.5)

6 (6.4)

 Dementia, n (%)

7 (5.2)

4 (4.3)

 End-stage renal disease, n (%) 

1 (0.7)

4 (4.3)

 Parkinson’s disease, n (%)

1 (0.7)

2 (2.1)

 Others, n (%)a

55 (41)

34 (36.6)

Primary site of neoplasm

 Colorectum, n (%)

25 (18.7)

17 (18.3)

 Bronchus and lung, n (%)

25 (18.7)

12 (12.9)

 Liver and bile duct, n (%)

15 (11.2)

12 (12.9)

 Breast, n (%)

12 (9)

7 (7.5)

 Head and neck, n (%)

9 (6.7)

8 (8.6)

 Others, n (%) b

48 (35.8)

37 (39.8)

Metastasis

 Lymph node, n (%)

64 (47.8)

48 (51.6)

 Lung, n (%)

57 (42.5)

39 (41.9)

 Liver, n (%)

48 (35.8)

38 (40.9)

 Bone, n (%)

41 (30.6)

24 (25.8)

 Peritoneum, n (%)

20 (14.9)

20 (21.5)

 Pleura, n (%)

19 (14.2)

16 (17.2)

 Brain, n (%)

11 (8.2)

10 (10.7)

 Others, n (%)

23 (17.2)

20 (21.5)

Cancer treatments

 Chemotherapy, n (%)

79 (59)

59 (63.4)

 Surgery, n (%)

63 (47)

46 (49.5)

 Radiotherapy, n (%)

61 (45.5)

34 (36.6)

 Targeted therapy, n (%)

13 (9.7)

9 (9.7)

 Other, n (%)

6 (4.5)

3 (3.2)

PPS at the initial palliative referral mean (SD)

44.8 (17.7)

49.8 (15)

 10–40%, n (%)

72 (53.73)

33 (35.48)

 50–90%, n (%)

62 (46.27)

60 (64.52)

Caregiver and family data

Place of living

 Home, n (%)

131 (97.8)

92 (98.9)

 Nursing home, n (%)

3 (2.2)

1 (1.1)

Having caregiver(s), n (%)

124 (92.5)

85 (91.4)

Caregiver type

 Paid caregiver, n (%)

8 (6.4)

7 (8.2)

 Family caregiver, n (%)

113 (91.1)

75 (88.2)

 Both, n (%)

3 (2.4)

3 (3.5)

Number of caregivers

 1 person, n (%)

99 (81.8)

64 (77.1)

  > 1 person, n (%)

22 (18.2)

19 (22.9)

Family household members

 1–4 persons, n (%)

89 (67.9)

66 (71.7)

  > 4 persons, n (%)

42 (32.1)

26 (28.3)

Palliative care service data

Place of initial palliative care consultation

 Outpatient, n (%)

43 (32.1)

38 (40.9)

 Inpatient, n (%)

87 (64.9)

51 (54.8)

 ED, n (%)

4 (3)

4 (4.3)

Time from initial palliative consultation to study endpoints

  < 16 days, n (%)

26 (19.4)

23 (24.7)

 16–100 days, n (%)

78 (58.2)

65 (69.9)

  > 100 days, n (%)

30 (22.4)

5 (5.4)

Advance care plan discussion, n (%)

126 (94)

85 (91.4)

Presence of advance directives, n (%)

9 (6.7)

5 (5.4)

Palliative home visit, n (%)

31 (23.1)

25 (26.9)

Number of home visits

 1 time, n (%)

21 (15.7)

15 (16.1)

  > 1 time, n (%)

10 (7.4)

10 (10.7)

Patient status at the study endpoints

 Death, n (%)

79 (59)

67 (72)

 Alive, n (%)

33 (24.6)

12 (12.9)

 Referral, n (%)

5 (3.7)

4 (4.3)

 Loss to follow-up, n (%)

17 (12.7)

10 (10.7)

  1. aOther co-morbidities include Benign prostatic hyperplasia 20 participants, COPD 16 participants, Gout 12 participants, Osteoporosis 10 participants, Chronic hepatitis B infection 9 participants, Psychiatric illnesses 9 participants, Pulmonary tuberculosis 7 participants, Osteoarthritis 6 participants, and HIV 6 participants
  2. bOther primary sites of neoplasm include soft tissue sarcoma in 2 patients, small bowel cancer in 2 patients, germ cell tumor in one patient, genitourinary cancer in 5 patients, malignant melanoma in 2 patients, peritoneal cancer in one patient, skin cancer in 2 patients, and unknown primary in 70 patients